Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited ...

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...

Poll: Which of the following is true about insulin products and the BPCIA?

At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence ...

Niazi, PhD, provides an overview of the current biosimilar education material offered by the FDA, emphasizing that manufacturer-developed materials aren't needed. Number 4: Blue Shield of California ...

At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for ...

At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen ...

At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global ...